Posadas

Researchers are investigating new treatments for metastatic cervical cancer, which is cancer that has spread beyond the cervix, the lower part of the uterus. This study evaluates the safety and effectiveness of the antibody drug conjugate sacituzumab tirumotecan sac-TMT combined with pembrolizumab and bevacizumab. The goal is to find out if these treatments, given together or with some variations, help patients live longer or delay cancer progression compared to standard care. The study has two parts. In Part 1, participants receive sac-TMT, pembrolizumab, and bevacizumab together to assess safety. In Part 2, all participants first get standard induction treatment with pembrolizumab, paclitaxel, and cisplatin or carboplatin, possibly with bevacizumab. Those whose cancer does not worsen then enter maintenance treatment, where they are randomly assigned to receive either pembrolizumab alone or sac-TMT plus pembrolizumab, with optional bevacizumab. Participants are involved for up to about 20 months during maintenance treatment after up to 4 months of induction. The study monitors safety by tracking side effects and treatment discontinuations. Effectiveness is measured by progression-free survival and overall survival up to several years. Quality of life and physical functioning are also assessed through questionnaires. Treatments and evaluations occur through regular intravenous infusions and periodic monitoring visits.

This research aims to collect real world evidence on adult patients in Argentina diagnosed with acute promyelocytic leukemia APL who receive first-line treatment using arsenic trioxide plus all trans retinoic acid ATOATRA based regimens. The study evaluates outcomes including event-free survival and overall survival, with additional focus on complete molecular response rates, treatment toxicity, early mortality, and the prognostic role of the FLT3 mutation. Patients will follow local guidelines where risk is determined by white blood cell counts high-risk WBC >10,000 or low-risk WBC <10,000. All patients receive induction with daily ATO plus ATRA until remission or for up to 60 days. High-risk patients also receive 2-3 doses of idarubicin at induction start. Consolidation includes cycles of ATO given 5 days a week in alternating 4-week periods and ATRA in alternating 2-week periods. Central nervous system prophylaxis is provided for high-risk patients or those with CNS bleeding. Participants will be monitored through molecular testing at consolidation end and periodically for high-risk patients during the first two years. Researchers will collect data on survival outcomes, molecular remission, toxicity, and early mortality. The study involves following patients over 36 months to assess long-term treatment effects and prognostic markers.